|
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)
NCT ID : NCT07225946
Protocol Number : KLK2-PASenger
Phase : 3
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (ABLE-32)
NCT ID : NCT06510374
Protocol Number : 000423
Phase : 3
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis (LUNAR)
NCT ID : NCT06668493
Protocol Number : 25-128
Phase : 1, 2
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT ID : NCT06991556
Phase : 2
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT ID : NCT05987241
Phase : 2/3
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT ID : 05803941
Phase : 4
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01)
NCT ID : 06120491
Phase : 3
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT ID : 05483868
Phase : 1
Location : Saint John's Cancer Institute
|
Jennifer Linehan, M.D.
|
|
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)
NCT ID : 06235151
Phase : 3
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
|
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
NCT ID : 03972657
Protocol Number : R5678-ONC-1879
Phase : 1/2
Location : Saint John's Cancer Institute
|
Przemyslaw Twardowski, M.D.
|
